SPY414.78-1.29 -0.31%
DIA339.65-1.66 -0.48%
IXIC13,921.32-28.90 -0.21%

DJ Eli Lilly's Mirikizumab Meets Main Endpoints in 12-Week Phase 3 Induction Study >LLY

· 03/16/2021 07:13

Please log in to view news